Mismatch repair-deficient (dMMR) with microsatellite instability-high (MSI-H) colorectal cancer

A special CRC subtype characterized by a high tumor mutational burden (TMB), more tumor neoantigens, and a higher density of tumor infiltrating lymphocytes. 

These immunogenic features make dMMR CRC highly responsive to treatment with PD-1 blockade. 

dMMR CRC is not benefited by neoadjuvant chemotherapy.

PD-1 blockade of dMMR CRC is highly effective with objective response rates in all patients, and 60% achieving pathologic complete response.

100% of patients with localized dMMR rectal cancer achieves a complete remission after six months of treatment PD-1 blockade.

Results of neoadjuvant immunotherapy for localized dMMR CRC show high rates of major and complete pathological response (Emilojou O).

Leave a Reply

Your email address will not be published. Required fields are marked *